Eddingpharm Starts China Trial of Amarin's Hypertriglyceridemia Treatment

Amarin reported that Eddingpharm, its China partner, has started a China registrational trial of Vascepa® (icosapent ethyl), a treatment for hypertriglyceridemia. Three years ago, Eddingpharma in-licensed greater China rights to the drug in a deal worth up to $169 million. Vascepa is a very pure, omega-3 fatty acid product available by prescription. In its US trial, Vascepa lowered triglycerides by 33% without causing any severe side effects. More details.... Stock Symbol: (NSDQ: AMRN) Share this with colleagues: // //